MedRegen LLC – Clinical stage pharmaceutical company

banner-2

MEDICINES FOR

REGENERATION

MedRegen develops drugs to restore injured organs and tissues
through regeneration and immunomodulation.

Banner 2

DISCOVERY, DEVELOPMENT

& COMMERCIALIZATION

MedRegen is dedicated to the development of
innovative therapies with the intent to improve
outcomes in patients suffering from life-
threatening diseases.

Homepagemain

MRG-001 Pipeline

MedRegen’s pipeline encompasses a broad range of diseases characterized by tissue injury and inflammation.

LATEST NEWS & BLOGS

By medregenOctober 30, 2024November 18, 2024

Phase II ARDS IND Submission China (NMPA)

In our effort to launch an international phase II trial in ARDS (NCT06308926), Medregen has also successfully submitted an IND for...

By medregenSeptember 14, 2024November 16, 2024

Phase II Wound Healing Study Completed

Northwestern University has completed recruitment and follow-up of all 10 subjects in the study. The database is expected to be cl...

By medregenMay 3, 2024November 16, 2024

FDA Phase II IND Approval (ARDS)

Medregen is excited to announce that the FDA has approved our IND to initiate a phase IIa, dose-ranging study (NCT06308926) in Acu...

Seraphinite Accelerator

Optimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.